Digital Aria Co Ltd (115450) - Total Liabilities
Based on the latest financial reports, Digital Aria Co Ltd (115450) has total liabilities worth ₩54.79 Billion KRW (≈ $37.13 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Digital Aria Co Ltd to assess how effectively this company generates cash.
Digital Aria Co Ltd - Total Liabilities Trend (2011–2025)
This chart illustrates how Digital Aria Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Digital Aria Co Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Digital Aria Co Ltd Competitors by Total Liabilities
The table below lists competitors of Digital Aria Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Chicago Atlantic BDC, Inc.
NASDAQ:LIEN
|
USA | $24.33 Billion |
|
Selan Exploration Technology Limited
NSE:SELAN
|
India | Rs1.45 Billion |
|
Shanghai Jinqiao Export Processing Zone Development Co Ltd B
SHG:900911
|
China | $32.26 Billion |
|
VietinBank Securities JSC
VN:CTS
|
Vietnam | ₫9.56 Trillion |
|
SHANGH.DAZ.PUBL.UTIL.YC 1
F:6WL
|
Germany | €12.82 Billion |
|
Heron Therapeuti
NASDAQ:HRTX
|
USA | $234.06 Million |
|
Sierra Madre Gold and Silver Ltd
V:SM
|
Canada | CA$12.17 Million |
|
Hathway Cable & Datacom Limited
NSE:HATHWAY
|
India | Rs10.01 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Digital Aria Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Digital Aria Co Ltd.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.84 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Digital Aria Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Digital Aria Co Ltd (2011–2025)
The table below shows the annual total liabilities of Digital Aria Co Ltd from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩54.79 Billion ≈ $37.13 Million |
-12.09% |
| 2024-12-31 | ₩62.33 Billion ≈ $42.24 Million |
+112.90% |
| 2023-12-31 | ₩29.28 Billion ≈ $19.84 Million |
-58.73% |
| 2022-12-31 | ₩70.94 Billion ≈ $48.07 Million |
-0.14% |
| 2021-12-31 | ₩71.03 Billion ≈ $48.14 Million |
+117.99% |
| 2020-12-31 | ₩32.58 Billion ≈ $22.08 Million |
-56.89% |
| 2019-12-31 | ₩75.58 Billion ≈ $51.22 Million |
+93.83% |
| 2018-12-31 | ₩38.99 Billion ≈ $26.43 Million |
+60.68% |
| 2017-12-31 | ₩24.27 Billion ≈ $16.45 Million |
+36.58% |
| 2016-12-31 | ₩17.77 Billion ≈ $12.04 Million |
-12.31% |
| 2015-12-31 | ₩20.26 Billion ≈ $13.73 Million |
-43.71% |
| 2014-12-31 | ₩36.00 Billion ≈ $24.40 Million |
+36.85% |
| 2013-12-31 | ₩26.31 Billion ≈ $17.83 Million |
-34.61% |
| 2012-12-31 | ₩40.23 Billion ≈ $27.26 Million |
-8.26% |
| 2011-12-31 | ₩43.85 Billion ≈ $29.72 Million |
-- |
About Digital Aria Co Ltd
HLB Therapeutics Co.,Ltd., a biotech company, develops pharmaceutical products in South Korea and internationally. It is developing GBT-201 using Thymosin beta for the treatment of ophthalmic diseases, such as dry eye syndrome and neurotrophic keratopathy; and OKN-007 for the treatment of glioblastoma brain tumor. It is also involved in the wholesale of vaccines, as well as manufactures electrica… Read more